FDA Peptide Reclassification 2026: What Actually Changed

On 27 February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview (The Joe Rogan Experience, episode 2461) that roughly 14 of 19 peptides on the FDA's Category 2 list would move back to Category 1. That statement is real and traceable to that interview and to contemporaneous reporting of it, rather than to any FDA document. What followed in the FDA's own records was something different, and the gap between the two explains almost every confused headline since.

This page tracks the regulatory sequence only. It does not cover what any of these compounds do, how they are made, or what the research shows. Those questions belong to the science pages linked throughout.

Where the record actually stands right now

Status: advisory recommendation issued, no rule proposed. Verified against FDA's own pages as published on 17 September 2026.

Three separate things happened in 2026, and the internet keeps compressing them into one. In April, a group of peptide nominations was withdrawn by the people who filed them, and FDA moved those substances off the Category 2 table into a separate list of withdrawn nominations. In July, an FDA advisory committee voted on whether seven of those peptide groups should go on the formal 503A Bulks List. And since July, nothing has been finalised.

No FDA document states that any peptide moved from Category 2 into Category 1 during 2026.

What each 2026 event did and did not do

The three categories, and what they are for

FDA's interim policy sorts nominated bulk drug substances into three buckets while it works through them. The categories are an enforcement posture, not a verdict.

Category 1 covers substances nominated with enough supporting information for FDA to evaluate, that do not appear on another relevant list. For these, FDA has said it does not intend to act against a compounder, provided the conditions in the guidance are met. That conditional phrasing is the whole point. Category 1 is a statement about what FDA intends to do, not a finding that a substance is safe or effective.

Category 2 covers substances FDA could evaluate but where it identified significant safety risks pending further work. FDA has said it would consider action against a compounder using these under its general enforcement policies. That is materially more restrictive than Category 1, and it is still not a statutory ban.

Category 3 is the one most readers skip. These substances were nominated with insufficient supporting information for FDA to evaluate them at all. Category 3 is a paperwork finding, not a safety finding, and a substance can be re-nominated with better support. Treating Category 3 as a milder Category 2 gets the meaning backwards.

One detail reshapes all of this. FDA's guidance states it does not intend to place substances nominated on or after 7 January 2025 into any of these categories. The three-category framework is a closing chapter, not a permanent classification system, which is why reading current peptide status through it produces odd answers.

Why "Category 2 to Category 1" is the wrong description

The February statement described an intended outcome. The April action produced a different one.

When a nominator withdraws a nomination, the substance stops moving through the evaluation pathway. It does not advance to the next stage of it. FDA's safety-risk page, current as of 22 April 2026, separates two tables: substances still in Category 2, and substances previously in Category 2 whose nominations were withdrawn. BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, emideltide (DSIP), injectable GHK-Cu, AOD-9604, CJC-1295, cathelicidin LL-37, Melanotan II, PEG-MGF, selank acetate, thymosin alpha-1 and dihexa acetate appear in the withdrawn table.

The withdrawn table is not Category 1. It is not a category at all. A substance sitting there is outside the Category 1 enforcement policy rather than inside it, which is close to the opposite of what the popular framing claims.

What also did not happen: no primary FDA or HHS document has been published confirming that approximately 14 of 19 peptides were reclassified from Category 2 to Category 1 in February 2026. The statement was made. The implementing record was not.

Substances that stayed in Category 2

This is where the "14 of 19" framing breaks most visibly. Several peptides never left. FDA's current Category 2 table still lists them, and it lists them under specific pathways and routes.

Read that table slowly. Ipamorelin acetate is in two places at once for two different reasons. Kisspeptin-10 is 503A. GHRP-2 and GHRP-6 are 503B. There is no single "FDA peptide status" to look up, which is why any article offering one is guessing.

Where the 2023 starting point came from

The number that anchors every version of this story is 19, but it comes from Secretary Kennedy's own characterisation rather than from any FDA publication: FDA's current withdrawn-nominations table lists seventeen substances and carries no dates at all. What FDA did publish was a set of actions in September 2023, when it identified potential significant safety risks for a group of nominated bulk substances and placed them in Category 2. The dates in FDA's current table bear that out: most of the peptide entries still listed carry 29 September 2023, with ibutamoren mesylate's 503B entry dated earlier, on 29 December 2022.

What FDA wrote at the time is worth reading precisely, because it is consistently paraphrased into something stronger. The recurring language is that compounded drugs containing a given substance may pose a risk for immunogenicity for certain routes of administration, and that FDA had identified no or only limited safety information for the proposed routes, so the agency lacked sufficient information to know whether the drug would cause harm. That is a statement about missing information. It is not a finding that a substance is dangerous, and the difference matters when the same sentence gets recycled as "FDA banned it."

The route qualifier appears throughout and is routinely dropped. FDA's GHRP-2 entry names injectable and nasal administration specifically. Its GHK-Cu entry is scoped to injectable routes. A status claim that omits the route is not reporting the record accurately.

State pharmacy law is a separate gate

Even a completed federal rulemaking would not settle the question on its own. Section 503A compounding is practised under state licensure, and state boards of pharmacy apply their own rules on what may be compounded and under what conditions. Federal eligibility is a necessary condition, not a sufficient one.

This is why blanket statements that a peptide is "legal" or "illegal" in the United States tend to be wrong in both directions. The accurate form of the question names the pathway, the exact chemical form, the route, the federal list or category, and the jurisdiction. Change any one of those and the answer can change with it.

503A and 503B answer different questions

Section 503A covers state-licensed pharmacies and physicians compounding for an identified patient. Section 503B covers FDA-registered outsourcing facilities, which operate under CGMP requirements and a separate bulks list.

Under 503A, a bulk substance qualifies if it complies with an applicable USP or NF monograph, or is a component of an FDA-approved drug, or appears on the 503A Bulks List. None of the seven peptides reviewed in July satisfies the first two routes, which is precisely why the third was the question on the table. Under 503B the test is different again, running through the 503B Bulks List or a drug-shortage connection.

Because the eligibility tests differ, a 503A answer tells you nothing reliable about the 503B position for the same molecule. The five substances in the table above demonstrate that directly.

What the July 2026 committee actually did

The Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 and voted on seven peptide groups, each considered as two distinct bulk drug substances: a free base and an acetate.

FDA's briefing materials proposed that none of the fourteen forms be added to the 503A Bulks List. The committee disagreed on six of seven. Reported vote outcomes were the same for the free base and the acetate of each substance. FDA has not published minutes or a transcript for this meeting, so the outcomes below come from contemporaneous reporting of the public sessions and the FDA meeting record will supersede them when it publishes.

Two features of this record get lost in summaries. First, the committee reached a different conclusion from FDA's own reviewers on six consecutive substances, which is unusual and tells you the evidence base is contested rather than settled. Second, FDA evaluated named proposed uses, not the compounds in general. A recommendation tied to ulcerative colitis is not a recommendation for every purpose the market attaches to the same molecule.

The votes were close. Public reporting of the individual tallies varies in detail, so this page does not assert specific numbers. FDA had not published minutes or a transcript for this meeting at the time of writing; when it does, that record supersedes any secondhand tally.

What still has to happen

An advisory committee recommends. It does not legislate, and FDA is not bound by it.

To put a substance on the 503A Bulks List, FDA runs notice-and-comment rulemaking: a proposed rule, a public comment period, review of comments, then a final rule. As of 17 September 2026, no proposed rule covering these six peptides has published. There is no statutory deadline forcing one. The precedent worth knowing is that FDA published a proposed rule on ten other bulk substances in December 2016 and did not finalise until February 2019.

FDA has also indicated a further advisory consultation before the end of February 2027 covering cathelicidin LL-37, injectable GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF.

What none of this establishes

A Category 2 removal does not establish Category 1 placement, a safety determination, Bulks List inclusion, or authorisation to compound.

A committee recommendation does not establish FDA adoption, a rule, an approval, or lawful compounding in any state.

Published research on a molecule does not establish regulatory eligibility for it. The two run on separate tracks, and FDA's July review is a clear illustration: reviewers described the available human safety information for several of these substances as limited or absent while the scientific literature on them continues to grow. How we weigh those evidence types is set out in our evidence grading approach, and the analytical side of the same problem is covered in what contamination data shows about peptide purity testing.

Commercial availability establishes least of all. A substance can be widely sold, actively researched, and still sit outside every compounding pathway FDA operates.

How to check this yourself

Two FDA pages hold most of the answer, and both carry a visible "content current as of" date. The 503A bulk drug substances page defines the categories and states the January 2025 nomination cutoff. The safety-risks page holds the live Category 2 table and the separate withdrawn-nominations table.

One caution worth carrying. The 503A landing page describes the three categories but names no substances, so citing it for a claim about a specific peptide looks authoritative without actually supporting it. The substance-level content lives in the linked documents and tables, and that is where a status claim has to be checked.